The described anti-TOSO CAR T cells have a strongly improved selectivity of target cell killing. The reduction of adverse effects on normal cells provides a competitive advantage against all other CAR T cell approaches that are currently on the market.
Functional data have been generated in cell-based assays with allogenic and autologous CAR T cells showing selectivity and efficiency of target cell killing activity (original data available on a confidential basis).
A European patent application and a US patent application are pending.
On behalf of the University of Cologne, PROvendis offers a patent license as well as a research collaboration with licensing option.
Chmielewski M, Hombach AA, Abken H. Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front. Immunol. 2013; 4: 371.
Cheadle EJ, et al. Chimeric antigen receptors for T-cell based therapy. Methods Mol. Biol. 2012; 907:645-66.